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Introduction
Adenomyosis is a disorder characterized by the pres-
ence of heterotopic endometrial glands and stroma in
the myometrium with adjacent myometrial hyperplasia
[1]. By definition, it consists of epithelial as well stromal
elements, and is situated at least 2.5 mm below the
endometrial–myometrial junction [2]. The disease ap-
pears in two forms, the diffuse type, known as adeno-
myosis, and the focal type, known as adenomyoma
[3–5]. Any site in the uterus may be involved, but the
posterior wall is affected the most [6]. In the past, the
diagnosis relied on clinical manifestations, with the most
frequently cited profile composed of the triad of abnor-
mal uterine bleeding (50%), secondary dysmenorrhea
(30%), and an enlarged, tender uterus [7].
Remarkable developments in imaging modalities,
including high-resolution ultrasound and magnetic
resonance imaging (MRI), have enhanced diagnostic
accuracy, as proven by several studies [3–6,8–10]. 
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SUMMARY
Extensive adenomyosis (adenomyosis) or its variance, localized adenomyosis (adenomyoma) of the uterus, is
often described as scattered, widely-distributed endometrial glands or stromal tissue found throughout the myo-
metrium layer of the uterus. By definition, adenomyosis consists of epithelial as well as stromal elements, and is
situated at least 2.5 mm below the endometrial–myometrial junction. However, the diagnosis and clinical signif-
icance of uterine adenomyosis and/or adenomyoma remain somewhat enigmatic. The relationship between
infertility and uterine adenomyosis and/or adenomyoma is still uncertain, but severe endometriosis impairs the
chances of successful pregnancy when using artificial reproductive techniques. To date, there is no uniform agree-
ment on the most appropriate therapeutic methods for managing women with uterine adenomyosis and/or
adenomyoma who want to preserve their fertility. Fertility has been restored after successful treatment of ade-
nomyosis using multiple modalities, including hormonal therapy and conservative surgical therapy via laparoscopy
or exploratory laparotomy, uterine artery embolization, and other methods, including a potential but under-
investigated procedure, magnetic resonance-guided focused ultrasound. This review will explore recent publica-
tions that have addressed the use of different approaches in the management of subfertile women with uterine
adenomyosis and adenomyoma. [Taiwan J Obstet Gynecol 2009;48(3):232–238]
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Adenomyosis and Adenomyoma
The characteristics of transabdominal ultrasound include
a honeycomb pattern, sonolucent 5–7 mm spaces, myo-
metrial cysts, wide posterior wall, eccentric endometrial
cavity, diffuse uterine enlargement but with no leiomy-
omas, and diminished uterine echogenicity [6]. How-
ever, the sensitivity and specificity of transabdominal
ultrasound for the diagnosis of uterine adenomyosis 
is around 50% [11]. Transvaginal ultrasound may be
superior to transabdominal ultrasound for the diagno-
sis of uterine adenomyosis since the diagnostic sensi-
tivity and specificity are over 50%, ranging from 50% to
100% for both [6]. The characteristic findings of uter-
ine adenomyosis using transvaginal ultrasound include
(1) increased size, asymmetry, retroversion, globular
or spherical shape, and uterosacral ligament nodular-
ity for uterine body examination; (2) focal honeycomb,
scattered, irregular, cystic, anechoic lacunae, asym-
metrical thickening of the anterior or posterior uterine
wall, heterogeneous increased or decreased myome-
trial echoes, mottled texture, lesions surrounded by
anechoic shadows 1–3 mm in diameter, hyperechogenic
or hypoechogenic striations, indistinct margins, non-
encapsulated myometrial lesion, myometrial linear stri-
ation for the myometrium examination; and (3) a shaggy
endometrial stripe, blurred endometrial–myometrial bor-
der, and thickened or distorted endometrium for the
endometrium examination [6]. The presence of suben-
dometrial echogenic linear striations, a globular config-
uration and myometrial cysts on transvaginal ultrasound
supports the diagnosis of adenomyosis [3]. Among the
transvaginal ultrasound diagnostic findings of adeno-
myosis, subendometrial linear striations have the highest
diagnostic accuracy [3].
MRI is also an accurate, noninvasive modality for
diagnosing adenomyosis and may be more helpful than
transvaginal ultrasound in distinguishing adenomyosis
from a leiomyoma, which is perhaps the most clinically
important distinction [12]. In addition, MRI may be
more effective for both diffuse and focal adenomyosis,
with sensitivity and specificity comparable to or even
better than those of ultrasound, as it depicts contrasts
between low-intensity lesions and surrounding tissue
[6]. The characteristic findings of MRI in uterine ade-
nomyosis include a minimum width of the junction
zone of 5 mm or 12 mm, a focal and uneven width of
the junction zone, low intensity of the junction zone,
high-intensity spots scattered in the junction zone, and
indistinct junction zone margins for the myometrium
examination [6]. Histologically, areas of low signal in-
tensity correspond to smooth muscle hyperplasia, and
bright foci on T2-weighted images correspond to islands
of ectopic endometrial tissue and cystic dilatation of
glands [12]. When menstrual hemorrhage occurs within
these ectopic endometrial tissues, signal intensity on
T1-weighted images may become high [12].
Even with advanced modern imaging technology,
there is no definitive method to diagnose adenomyosis
or its related diseases. The classical signs and clinical
symptoms may suggest the diagnosis, but these signs
and symptoms are, unfortunately, often misleading. In
addition, without tissue proof, the diagnosis of uterine
adenomyosis is controversial; therefore, of the mini-
mally invasive diagnostic methods, myometrial biopsy
has been used by several authors and seems promising
[2,13,14].
Parallel to the development of improved diagnostic
methods for adenomyosis, innovative modalities have
been introduced as alternatives therapies, such as med-
ical treatment, conservative surgical treatment, uterine
artery embolization and laparoscopic uterine vessel oc-
clusion, for those women for whom hysterectomy would
not be considered an option [2,13–17]. The purpose
of this review is to focus on the role of different thera-
pies in managing subfertile women with symptomatic
uterine adenomyosis and adenomyomas.
Fertility and Adenomyosis and/or
Adenomyomas
An association between adenomyosis and subfertility
has not been fully established. Some believe that ade-
nomyosis is not associated with subfertility, because it
is widely held to be a condition associated with multi-
parity, and there have been several pathology-based
studies published in which women with adenomyosis
found at hysterectomy were often more parous than
women in whom it was not found [18,19]. However, the
possibility of an association between adenomyosis and
subfertility has been raised in a few small case series and
in a sole case report [1,7,8,17,20–34]. In this, fertility
was restored after the successful treatment of adeno-
myosis with multiple modalities, including hormonal
therapy and conservative surgical therapy via laparos-
copy or exploratory laparotomy, uterine artery embo-
lization (UAE) [17], and other methods, including a
potential but under-investigated procedure, magnetic
resonance-guided focused ultrasound (MRgFUS) [34].
Medical Treatment
Gonadotropin-releasing hormone (GnRH) agonist may
be the most popular and well-accepted therapy. In fact,
this strategy has resulted in a few case reports of success-
ful pregnancy and delivery [14,22–25,27]. The reason
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for the improved reproductive performance in these
patients is not well understood. It may be explained by
the fact that GnRH agonist transiently suppresses the
hypothalamus-pituitary gland-ovary axis and induces
a hypoestrogenic effect with resultant shrinkage of the
uterine adenomyosis (a reduced uterine size) and relief
of the symptoms (a suppressed uterine adenomyosis).
Furthermore, GnRH agonist is reported to possibly
promote uterine and endometrial receptivity [2,24].
However, its effect is often transient and it is frequently
used with a preoperative adjuvant therapy [1]. Rapid
regrowth of adenomyosis and relapse of symptoms
and signs always occurs after the treatment is stopped
[14]. This phenomenon was similar to that in the 
use of GnRH agonist in the management of uterine
myomas [35–40].
In a review of the use of GnRH agonist as conserva-
tive therapy for adenomyosis with successful pregnancy
[14], nine women experienced spontaneous concep-
tion, and one had a successful term vaginal delivery with
the use of surgical resection followed by 3 months of
danazol delivery [1]. All pregnancies, indeed, occurred
within 12 months after completing therapy or the return
of the first menstruation, ranging from: immediately
to 1 month [23–25], 2–4 months [24,30,31], 5 months
[27], and 6 months [30], strongly suggesting that spon-
taneous pregnancy as a result of using GnRH agonist in
these subfertile women with extensive uterine adeno-
myosis may be possible, but the effective period may be
short if pregnancy is achieved. Previously, we studied
37 women with a clinic-pathologic diagnosis of uter-
ine adenomyosis who were treated with GnRH agonist
alone, and only three subfertile women had concep-
tion and finally a successful delivery [14]. Consistent
with the above, all pregnancies in our study [14] also
occurred within 12 months of completing medical
therapy or the return of the first menstruation.
In summarizing the role of GnRH agonist for induc-
ing spontaneous pregnancy in these subfertile women
with extensive adenomyosis, nearly all spontaneous
pregnancies occurred within 6 months after treatment
or the return of the first menstruation (Table), so we
suggest that further active management is highly rec-
ommended if pregnancy does not occur within the
first year or 6 months after completing therapy or the
return of menstruation.
Table. Summary of outcomes of subfertile women with adenomyosis and/or adenomyoma after different therapeutic
strategies
Authors Treatment
Interval between spontaneous pregnancy and 
completed treatment (mo)
Wang et al [14] GnRH agonist < 12
Grow and Filer [23] GnRH agonist ∼1
Hirata et al [24] GnRH agonist ∼1
2–4
Nelson and Corson [25] GnRH agonist ∼1
Silva et al [27] GnRH agonist ∼5
Huang et al [30] GnRH agonist 2–4
∼6
Lin et al [31] GnRH agonist 2–4
Rabinovici and Stewart [42] MRgFUS 2–4
Wang et al [14] Conservative surgery 4–24
Wang et al [33] Conservative surgery ∼30
Wang et al [53] Conservative surgery 3–19
Fujishita et al [56] Conservative surgery ∼4
∼6
Strizhakov et al [57] Conservative surgery < 12
Wang et al [14] Combined therapy 3–34
Wood [20] Combination therapy* ?
Huang et al [29] Combined therapy ∼7
Wang et al [32] Combined therapy ∼3
∼12
Wang et al [33] Combined therapy (with danazol) ∼21
Wang et al [53] Combined therapy 3–22
*Combination of any type of conservative surgery and medical treatment (gonadotropin-releasing hormone agonist). GnRH = gonadotropin-releasing hormone;
MRgFUS = magnetic resonance-guided focused ultrasound.
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Uterine Artery Embolization
UAE was first reported for the treatment of leiomy-
omata in 1995 [41]. Since that time, there has been
rapid growth in the use of this treatment, and UAE has
emerged in the past decade as a relatively safe, minimally
invasive alternative therapy for uterine fibroids [42].
An increasing number of reports indicate that uterine
fibroids can be successfully treated with UAE, and this
technique seems to be a promising treatment for women
who want to retain their uterus. The rationale for using
laparoscopic uterine vessel occlusion in the management
of symptomatic fibroids is found in the successful expe-
rience with UAE, Since then, it has become increasingly
accepted as a minimally invasive, uterine-sparing pro-
cedure, and studies have reported relief of excessive
menstrual bleeding or pressure in 80–90% of patients
[43–47]. Laparoscopic uterine vessel occlusion provided
similar relief of symptoms (89.4% with symptomatic
improvement and 21.2% with complete resolution of
symptoms) in 2001 in a 7- to 12-month follow-up of
87 patients [48].
Adenomyosis and uterine fibroids coexist in many
uteri, and their symptoms are often similar [42]. Thus,
performing UAE in women with symptomatic uterine
fibroids will ultimately also include patients with ade-
nomyosis. Because of the difficult differential diagnosis
between the two entities, it can be assumed that if the
embolization procedure is performed without a screen-
ing MRI examination, patients with undiagnosed ade-
nomyosis are also being treated [49].
Pregnancies and vaginal deliveries seem to be pos-
sible after UAE for adenomyosis [42]. In a report on
eight pregnancies in six patients after UAE, three women
had adenomyosis and one woman had both uterine
fibroids and adenomyosis [17]. One woman with ade-
nomyosis delivered twice, once at 34 weeks’ gestation
and once at term. All neonates but one (premature rup-
ture of membranes and 1,850 g birth weight at 34
weeks’ gestation) were healthy and appropriate for their
gestational age at delivery. Despite the small number of
pregnancies, the authors argued that UAE with poly-
vinyl alcohol particles did not affect the fertility and
pregnancy outcome [17].
Although it is reported that UAE has not shown an
effect on fertility [2], a recent publication evaluating
the midterm clinical and first reproductive results of
the comparison between UAE and myomectomy is
worthy of our attention. This study showed that myo-
mectomy appears to have superior reproductive out-
comes in the first 2 years after treatment compared
with UAE in the management of uterine myomas [50].
Therefore, some papers suggested that myomectomy
should be recommended as the treatment of choice
over UAE in most patients desiring future fertility [51],
even though most pregnancies following UAE have good
outcomes [52]. In view of this, the policy of conservative
surgery for adenomyosis and/or adenomyoma is simi-
lar to that of myomectomy for myoma, suggesting that
conservative surgery may have been without detriment
to reproductive performance [14,53].
Magnetic Resonance-guided Focused
Ultrasound
Since ultrasound waves carry energy, the ability of these
waves to cause a rise in tissue temperature was recog-
nized long ago, and if the pattern of the waves is modi-
fied so that they meet at a single point, one can achieve
a localized high temperature rise at this focal point [42].
Using this technique, irreversible cell damage (60–90°C)
can be generated within a few seconds at such a focal
point [42]. Heating tissue to temperatures above 55°C
leads to protein denaturation and irreversible cell death
through coagulative necrosis [42]. Based on these char-
acteristics, high-intensity focused ultrasound surgery has
been proposed in the past as a noninvasive technique
to treat soft tissue tumors deep in the body. Under 
the guidance of MRI, a brand-new tool, MRgFUS, has
been used to treat uterine fibroids in more than 1,200
women who chose not to undergo hysterectomy, with
promising results [42]. In a review by Rabinovici and
Stewart [42], at least nine patients were treated with
MRgFUS. One patient conceived spontaneously three
menstrual cycles after MRgFUS, and the pregnancy
course was uneventful; she gave birth to a full-term
healthy baby girl weighing 3.050 kg, after an uneventful
labor and vaginal delivery [34].
Surgical Treatment
By contrast, and compared with the well-accepted
GnRH agonist as a choice in the management of symp-
tomatic and/or subfertile women with extensive ade-
nomyosis, surgical intervention is seldom considered
to play a role in managing such patients. The most
important consideration is the difficulty of selecting a
good candidate to undergo the surgical approach; for,
how does one determine the extent of adenomyosis in
a particular patient? Furthermore, adenomyosis is not
cleared completely by conservative surgery, and post-
operative sequelae, such as pelvic adhesion, future uter-
ine deformities, intrauterine adhesions and reduced
uterine capacity [2], cannot be completely avoided. 
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Yet another late complication is subsequent uterine
scars which may conceal more adenomyotic foci and
result in the reduction of tensile strength [2]. There-
fore, the possible rupture of a pregnant uterus should be
cause for alarm, because as mentioned above, adeno-
myosis is always mixed with the surrounding normal
myometrium (which may impact on surgical treatment).
Hence, conservative excision of extensive adenomyosis
is very difficult to complete, with a resultant increasing
frequency of entering the uterine cavity during the oper-
ation (e.g. nearly 30% of patients in one study [14]), as
well as after removing the adenomyotic tissues. In addi-
tion, it is more difficult to repair the uterine defect,
compared with excising a uterine leiomyoma [54]. Since
rupture of a pregnant uterus has been observed after
myomectomy [55], it is reasonable to expect the possi-
bility of uterine rupture after excision of adenomyotic
tissue. Therefore, the decision to use conservative sur-
gery in the management of women with extensive
adenomyosis should be taken safely. We reviewed the use
of conservative surgery for the management of uterine
adenomyosis with successful pregnancy, with nine spon-
taneous conceptions and one rupture of the uterus at
12 weeks of gestation [20]. The interval between the
occurrence of the pregnancies and completed therapy
or the return of the first menstruation varied from 3 to
30 months (Table) [2,29,32,33,56,57].
Combination Therapy
Because of the transient effect of medical therapy and
the only 50% effectiveness of surgical therapy in man-
aging uterine adenomyoma-related diseases, the com-
bination of conservative surgery and medical treatment
with either GnRH agonist or danazol (surgical-medical
treatment) has been developed [53]. The results are
promising and welcome [14,29,32,33,53]. In a series
of 165 patients with symptomatic adenomyoma who
were treated with conservative surgery, regardless of
GnRH agonist treatment or not, data showed that this
treatment might be acceptable in the management 
of a selected population with severe symptomatic ade-
nomyoma [53]. Combination therapy provided more
effective symptom control (lower symptom relapse
rate) than conservative surgery alone during the 2-year
follow-up [53]. However, the reproductive outcomes
seemed to be similar between conservative surgery with
and without GnRH agonist treatment; there was no
statistical significant difference in either the clinical
pregnancy rate (79.5% in the combination therapy
group versus 74.1% in the conservative surgery alone
group) or the successful delivery rate (72.7% in the
combination therapy group versus 63.0% in the con-
servative surgery alone group). Therefore, it was con-
cluded that combination therapy might add some
benefits in improvement of reproductive performance
based on the findings of better symptom control and
a lower relapse rate, although no evidence has sup-
ported this hypothesis yet.
Conclusion
There is more evidence supporting the advantages of
conservative surgery or UAE, in providing not only
more effective symptom relief but also longer durable
symptom control for symptomatic women with uterine
adenomyosis and/or adenomyoma, compared with
medical treatment alone, such as GnRH agonist alone.
Furthermore, reproductive performance after conser-
vative surgery seemed to be improved compared with
that after GnRH agonist treatment; not only was there
a longer cumulative pregnancy rate, but also a higher
cumulative final successful delivery rate. Therefore, we
recommend that subfertile women with the diagnosis
of uterine adenomyosis or adenomyoma try GnRH
agonist treatment first; then, these women should un-
dergo an active therapy strategy to improve fecundity.
Pregnancy frequently occurs within 6 months after com-
pleting medical treatment. If no pregnancy occurs, con-
servative surgery, regardless of GnRH agonist treatment
or not, may be an alternative consideration in the man-
agement of severely symptomatic uterine adenomyosis
and/or uterine adenomyoma, not only for symptom
control, but also to increase reproductive performance.
Future research addressing the relationship between
adenomyosis/adenomyoma and fertility is worthwhile.
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